metformin has been researched along with palbociclib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bilodeau, M; Goyal, L; Hatting, M; Liang, J; Luo, C; Perry, EA; Puigserver, P; Sharabi, K; Sicinski, P; Srivastava, A; Tavares, CDJ; Zhu, AX | 1 |
2 other study(ies) available for metformin and palbociclib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency.
Topics: Animals; Antineoplastic Agents; Cyclin D1; Cyclin-Dependent Kinase 4; Diabetes Mellitus, Type 2; Hyperinsulinism; Hypoglycemic Agents; Liver Neoplasms, Experimental; Male; Metformin; Mice; Obesity; Piperazines; Protein Kinase Inhibitors; Pyridines; Up-Regulation | 2020 |